Changes in Liver Function Tests (LFTs) with Canagliflozin (CANA) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) Are Related to Changes in A1c and Body Weight (BW)

被引：0

|

作者：

Leiter, Lawrence A.

Forst, Thomas

Polidori, David

Balis, Dainius

Xie, John

Sha, Sue

机构：

来源：

DIABETES | 2015年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1265-P

引用

收藏

页码：A328 / A328

页数：1

相关论文

共 50 条

[1] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
[J]. DIABETES, 2014, 63 : A284 - A284
[2] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM) and Presumed Liver Fibrosis Suggestive of Nonalcoholic Steatohepatitis (NASH)
Polidori, David
Meininger, Gary
[J]. DIABETES, 2017, 66 : A348 - A348
[3] Time Until Insulin Initiation for Canagliflozin (CANA) vs. Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK
Schroeder, Melanie
Chan, Edmond
Willis, Michael
Johansen, Pierre
Nilsson, Andreas
Schubert, Agata
Neslusan, Cheryl
[J]. DIABETES, 2016, 65 : A327 - A327
[4] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
Lavalle Gonzalez, Fernando J.
Januszewicz, Andrzej
Davidson, Jaime
Qiu, Rose
Tong, Cindy
Meininger, Gary
[J]. DIABETES, 2013, 62 : A61 - A61
[5] Quality Measure (QM) Attainment in Overweight/Obese Patients with Type 2 Diabetes (T2DM) Treated with Canagliflozin (CANA) or Sitagliptin (SITA)
Bailey, Robert
Vijapurkar, Ujjwala
Martin, Silas
Meininger, Gary
Rupnow, Marcia
[J]. DIABETES, 2014, 63 : A270 - A270
[6] WEIGHT- AND HEALTH-RELATED QUALITY OF LIFE (WRQOL AND HRQOL) WITH CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM) ON BACKGROUND METFORMIN
Traina, S. B.
Ho, K. F.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A448 - A448
[7] Canagliflozin (CANA) Improves Risk Factors of Metabolic Syndrome (MetS) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) and MetS on Background Metformin (MET) plus Sulfonylurea (SU)
Davies, Michael J.
Merton, Katherine
Vijapurkar, Ujjwala
Balis, Dainius
Desai, Mehul
[J]. DIABETES, 2016, 65 : A286 - A286
[8] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
[J]. DIABETES, 2014, 63 : A284 - A284
[9] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
Pititto, L.
Neslusan, C.
Teschemaker, A. R.
Johansen, P.
Willis, M.
Asano, E.
Puig, A.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
[10] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
Martin, Silas
Neslusan, Cheryl
Vo, Lien
Teschemaker, Anna
Johansen, Pierre
Willis, Michael
[J]. DIABETES, 2014, 63 : A310 - A310

← 1 2 3 4 5 →